oxetacaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| local anaesthetics | 3407 | 126-27-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
isolated from bioactive leaf extracts of Rollinia mucosa
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hydronephrosis | 85.58 | 77.60 | 16 | 159 | 10646 | 63478201 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hydronephrosis | 72.99 | 49.45 | 16 | 274 | 17438 | 79726660 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C05AD06 | CARDIOVASCULAR SYSTEM VASOPROTECTIVES AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Local anesthetics |
| MeSH PA | D000777 | Anesthetics |
| MeSH PA | D000779 | Anesthetics, Local |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.47 | acidic |
| pKa2 | 5.07 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.64 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01152 | KEGG_DRUG |
| CHEBI:31947 | CHEBI |
| CHEMBL127592 | ChEMBL_ID |
| C100289 | MESH_SUPPLEMENTAL_RECORD_UI |
| C515333 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB12532 | DRUGBANK_ID |
| 001342 | NDDF |
| 111134000 | SNOMEDCT_US |
| 425185000 | SNOMEDCT_US |
| C0069758 | UMLSCUI |
| CHEMBL451445 | ChEMBL_ID |
| 4621 | PUBCHEM_CID |
| 1342 | INN_ID |
| IP8QT76V17 | UNII |
Pharmaceutical products:
None